MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Tissue Regenix CE Mark expected 6 months early

Tissue Regenix CE Mark expected 6 months early

By

Tissue RegenixTissue Regenix said today it expects to pick up CE Mark approval in the European Union for its OrthoPure XT and XM procine tendon and meniscus products approximately 6 months ahead of schedule.

Clinical trials are currently underway for both products, the company said, and positive clinical data from the trials has resulted in an accelerated date to CE Mark approval set for the end of 2016, 6 months ahead of previous estimates.

“The possibility of earlier EU approval for OrthoPure XT, and the potential for a US pilot study, would allow us to access these key markets via a more rapid regulatory route, where sales momentum can be quickly established, particularly with our ‘off the shelf’ alternative to the existing approaches. Positive data from the OrthoPure XM EU clinical trial, and the confirmation of a 510(k) route to the US market, means that we can undertake the additional study to implement improvements and pursue one common version of the product, expected for launch within the EU during 2018, and allow us to initiate the work required for US regulatory approval,” CEO Antony Odell said in a press release.

Tissue Regenix said the results have ‘encouraged’ it into applying for a U.S. pilot clinical trial with the FDA, expecting to submit it in the 4th quarter this year. The company added that it may be able to pursue 510(k) clearance for its OrthoPure XM.

Last August, Tissue Regenix put Kevin Barton on-point to direct U.S. sales and marketing for its dCell tissue regeneration device. The company’s new marketing VP hails from a wound care company Kinetic Concepts , where he was a senior product manager. Barton also formerly worked at Novartis, Sulzer Carbomedics and Dell Computer Corp.

In case you missed it

RSS From Medical Design & Outsourcing

  • The MedTech Conference by AdvaMed to be a mixture of in-person and virtual
    To hold an event or not to hold a live event. Medtech trade association AdvaMed chose both for The Medtech Conference, which takes place next week. The September 27–30 conference includes a mixture of virtual presentations and in-person events in Washington, D.C., and Minneapolis. AdvaMed CEO Scott Whitaker mentioned several conference agenda highlights during a… […]
  • Varta launches online battery monitoring feature
    Battery maker Varta has launched a cloud computing feature to let customers remotely monitor battery charging, health and the temperature of the battery management system. While Varta makes microbatteries for medical devices such as hearing aids, the new online monitoring dashboard is meant for its “Easy Block” and “Easy Blade” modular smart batteries. The smart… […]
  • Bionaut Labs wins humanitarian use device designation to treat rare pediatric brain disorder
    The microrobotics startup Bionaut Labs has announced that FDA has granted a humanitarian use device designation for the device known as BNL-201 to treat a Dandy-Walker syndrome, a congenital brain malformation affecting the cerebellum. According to the National Organization for Rare Disorders, the syndrome affects one out of every 25,000 to 35,000 live births. There… […]
  • Integer plans $30 million innovation and manufacturing facility in Galway
    Integer Holdings Corp. (NYSE: ITGR) plans to build a medical device innovation and manufacturing facility in the Parkmore East area of Galway, Ireland. Plano, Texas–based Integer said the initial phase of the project will total 60,000 square feet and a $30 million investment over the coming years, with construction scheduled from 2022 to late 2023… […]
  • Accu-Tube appoints Matthew Haddle as CEO
    Accu-Tube today announced that it has appointed Matthew Haddle as its new CEO. Prior to joining the Englewood, Colorado-based company, Haddle was GM of industrial coating services and equipment at Praxair Surface Technology. He has also held senior management positions at Albany Engineered Composites and Accellent. Get the full story on our sister site, Medical… […]
  • LightDeck picks GS Plastic Optics for COVID-19 test ramp up
    LightDeck Diagnostics has selected GS Plastic Optics to make optical components for its new COVID-19 antibody testing platform. Boulder, Colorado–based LightDeck developed a screening platform to deliver results as quickly as five minutes for SARS-CoV-2 ultra-rapid antigen and COVID-19 total antibody tests, using a laser waveguide with a consumable cartridge for each testing sample.  Rochester,… […]
  • Hologic’s first Global Women’s Health Index flags preventative care for improvement
    An estimated 1.5 billion women have not been tested in the past year for critical diseases, according to Hologic’s first Global Women’s Health Index. On behalf of diagnostic maker Hologic, the Gallup World Poll surveyed more than 60,000 women and girls (age 15 and older) across the world to measure action and attitudes about women’s… […]
  • Medicine-saving Nanodropper makes history in Minnesota Cup win
    The Minnesota Cup has awarded its grand prize for innovative entrepreneurs to a student-led startup for the first time. Medical device developer Nanodropper took home top honors from the awards ceremony, held yesterday at the University of Minnesota. “We have created an eyedrop bottle adaptor that will save billions in medication waste, one drop at… […]
  • Medtronic’s Hugo team ‘waiting for the phone call’ for approval in Europe
    It sounds like European approval of Medtronic’s soft tissue robotically-assisted surgery system, Hugo, could come any day now. “We’re sitting at the tip of our chair waiting for the phone call that the product will be approved,” Medtronic EVP and EMEA President Rob ten Hoedt said Friday. Fridley, Minnesota-based Medtronic (NYSE:MDT) filed for European approval… […]
  • Ivy Brain Tumor Center sees promise in sonodynamic therapy for glioblastoma
    Ivy Brain Tumor Center and its partner Sonalasense have announced positive initial results in a first-in-human Phase 0/1 clinical trial involving recurrent glioblastoma patients. Sonalasense has developed a sonodynamic therapy (SDT) that pairs low-intensity ultrasound with chemotherapeutic agents known as sonosensitizers. The therapy is noninvasive. Data from the trial indicate that SDT swiftly causes targeted… […]
  • Former Theranos scientist testifies to blood test inaccuracies prior to Walgreens deal in Elizabeth Holmes trial
    A former Theranos scientist testified on the inaccuracies of the company’s device during Elizabeth Holmes’ federal fraud trial. Surekha Gangakhedhar worked at Theranos from 2005 to 2013 and reported directly to Holmes at one point. She testified on Friday that Holmes allegedly pressured her to validate blood test results to speed up a rollout of… […]